Phase 1 · Complete
Platform architecture
Core stabilization and product integrity systems designed and validated across controlled environments.
Investor Overview
A licensing model with multi-asset applicability, priced into a $60B+ addressable market.
Investment thesis
HyGyHya is infrastructure for pharmaceutical-grade compound stabilization and product integrity, positioned across a large, underserved market.
Platform snapshot as of August 2026
2
Licensable systems
6×
Shelf-life extension
5
Addressable sectors
4
Science disciplines
$60B+
Addressable market
The thesis in four parts.
Core bottleneck
Addresses a fundamental constraint limiting scalability across plant-derived and complex therapeutics.
Platform exposure
Multi-asset applicability across compounds and development programs.
Dual architecture
Independent and integrated licensing through Stabilization and Product Integrity.
Regulatory alignment
Aligned with increasing emphasis on reproducibility, traceability, and integrity.
Licensable independently
Two systems with independent value.
Stabilization holds molecular integrity. Product Integrity holds lifecycle verification and supply chain trust. License either alone.
Platform roadmap
Phase 2 · Active
Partner engagement
Engaging with qualified pharmaceutical partners and investors for platform integration.
Phase 3 · Next
Licensing deployment
Independent and integrated licensing across pharmaceutical development pipelines.
Phase 4 · Future
Global scale
Multi-market deployment across therapeutic areas and geographies.
Built by experienced operators with scientific credibility.
Shawn Sizer
Co-Founder and Chief Executive Officer
View profileDr. James Woodford, Ph.D.
Co-Founder and Chief Science Officer
View profileDr. Robert F. Vogt, Ph.D.
Director of Regulatory Science and Platform Validation
View profileDon E. Wirtshafter
Strategic Advisor
View profilePatrick F. O'Reilly III
Intellectual Property Counsel
View profileRon Docie
Strategic Advisor
View profileInvestor questions
No. HyGyHya is a private company engaging with qualified investors and strategic partners directly. Technical brief, validation materials, and licensing discussions are available under confidentiality.
HyGyHya operates as a licensing platform with a dual-system architecture supporting independent and integrated licensing pathways. Revenue scales through partnerships across multiple compounds, programs, and geographies.
The platform addresses two fundamental constraints: molecular instability driving variability in pharmacokinetics and clinical outcomes, and lack of product-level verification undermining trust across supply chains. The addressable market exceeds $60 billion.
Use the Contact page or email info@hygyhya.com. HyGyHya is engaging with qualified investors, and appropriate materials are available under non-disclosure agreement.